Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals - PubMed (original) (raw)
Clinical Trial
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals
Masafumi Matsuda et al. Metabolism. 2002 Sep.
Abstract
This study sought to examine whether enhanced hepatic sensitivity to glucagon contributes to impaired glucose homeostasis in subjects with type 2 diabetes mellitus (T2DM). Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects received a 4-hour glucagon infusion at the rates of 0.2, 0.5, 2, 6, and 8 ng. kg(-1). min(-1) while maintaining the plasma insulin concentration constant at the basal level with exogenous infusions of somatostatin and insulin. On the evening prior to study, diabetic subjects received a low-dose insulin infusion at a rate designed to maintain euglycemia and this infusion rate was continued until the end of the glucagon infusion study on the following day. Each glucagon infusion study was performed on a separate day and in random order. 3-(3)H-glucose was infused in all studies to measure endogenous glucose production (EGP) and the rate of whole body glucose disposal. During the first 2 hours (0 to 120 minutes) of glucagon infusion, EGP increased sharply in both groups, and the initial rate of rise in EGP was higher in control versus diabetic subjects. During the last 2 hours (120 to 240 minutes) of glucagon infusion, EGP in the diabetics tended to be higher than controls during the 3 lower glucagon infusion rates and this difference reached statistical significance (P <.05 to.01) during the 6 and 8 ng. kg(-1). min(-1) infusions. During the 2 hours following cessation of glucagon (240- to 360-minute time period), the stimulation of glucose disappearance from plasma was impaired (P <.05) during all 5 glucagon infusion rates in the diabetics compared to controls. We conclude that in T2DM patients, the initial (0 to 120 minutes) stimulation of hepatic glucose output (which primarily reflects glycogenolysis) by glucagon is not enhanced in T2DM patients. The late (120 to 240 minutes) stimulation of hepatic glucose output (which primarily reflects gluconeogenesis) by glucagon tends to be increased, especially at supraphysiologic plasma glucagon concentrations.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Similar articles
- Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production.
Toft I, Jenssen T. Toft I, et al. Scand J Clin Lab Invest. 2005;65(4):307-20. doi: 10.1080/00365510510025692. Scand J Clin Lab Invest. 2005. PMID: 16076686 Clinical Trial. - Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.
Orskov L, Alberti KG, Mengel A, Møller N, Pedersen O, Rasmussen O, Seefeldt T, Schmitz O. Orskov L, et al. Diabetologia. 1991 Jul;34(7):521-6. doi: 10.1007/BF00403290. Diabetologia. 1991. PMID: 1916058 - Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
Nielsen MF, Wise S, Dinneen SF, Schwenk WF, Basu A, Rizza RA. Nielsen MF, et al. Diabetes. 1997 Dec;46(12):2007-16. doi: 10.2337/diab.46.12.2007. Diabetes. 1997. PMID: 9392488 - Control of hepatic glucose output by glucagon and insulin in the intact dog.
Cherrington AD, Chiasson JL, Liljenquist JE, Lacy WW, Park CR. Cherrington AD, et al. Biochem Soc Symp. 1978;(43):31-45. Biochem Soc Symp. 1978. PMID: 373768 Review. - Fat-induced liver insulin resistance.
Shah P, Basu A, Rizza R. Shah P, et al. Curr Diab Rep. 2003 Jun;3(3):214-8. doi: 10.1007/s11892-003-0066-1. Curr Diab Rep. 2003. PMID: 12762968 Review.
Cited by
- Ethnicity-related differences in mitochondrial regulation by insulin stimulation in diabetes.
Neikirk K, Kabugi K, Mungai M, Kula B, Smith N, Hinton AO Jr. Neikirk K, et al. J Cell Physiol. 2024 Aug;239(8):e31317. doi: 10.1002/jcp.31317. Epub 2024 May 22. J Cell Physiol. 2024. PMID: 38775168 Review. - High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans.
Gray SM, Goonatilleke E, Emrick MA, Becker JO, Hoofnagle AN, Stefanovski D, He W, Zhang G, Tong J, Campbell J, D'Alessio DA. Gray SM, et al. Diabetes. 2024 Mar 1;73(3):412-425. doi: 10.2337/db23-0201. Diabetes. 2024. PMID: 38015721 - Upregulated TGF-β1 contributes to hyperglycaemia in type 2 diabetes by potentiating glucagon signalling.
Xiao Y, Wang Y, Ryu J, Liu W, Zou H, Zhang R, Yan Y, Dai Z, Zhang D, Sun LZ, Liu F, Zhou Z, Dong LQ. Xiao Y, et al. Diabetologia. 2023 Jun;66(6):1142-1155. doi: 10.1007/s00125-023-05889-5. Epub 2023 Mar 14. Diabetologia. 2023. PMID: 36917279 - The Effect of Glucagon on Protein Catabolism During Insulin Deficiency: Exchange of Amino Acids Across Skeletal Muscle and the Splanchnic Bed.
James H, Gonsalves WI, Manjunatha S, Dasari S, Lanza IR, Klaus KA, Vella A, Andrews JC, Nair KS. James H, et al. Diabetes. 2022 Aug 1;71(8):1636-1648. doi: 10.2337/db22-0079. Diabetes. 2022. PMID: 35621914 Free PMC article. - S1P Signaling Pathways in Pathogenesis of Type 2 Diabetes.
He Q, Bo J, Shen R, Li Y, Zhang Y, Zhang J, Yang J, Liu Y. He Q, et al. J Diabetes Res. 2021 Jan 19;2021:1341750. doi: 10.1155/2021/1341750. eCollection 2021. J Diabetes Res. 2021. PMID: 34751249 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous